U.S. Food and Drug Administration (FDA) Approves PREZISTA(R) Once-Daily as Part of Combination Therapy for Treatment-Naive Adults with HIV-1.
-PREZISTA also granted traditional approval- BRIDGEWATER, N.J., Oct. 22 /PRNewswire/ -- The FDA has granted PREZISTA (darunavir) tablets, a protease inhibitor, approval for an expanded indication for once-daily dosing as part of HIV combination therapy in treatment-naive adults (those who have never taken HIV medication before). The...

Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia.
PARIS, October 23 /PRNewswire/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces positive results from its Phase II clinical trial evaluating NXL103 in the treatment of community acquired pneumonia (CAP). NXL103...

Anadys Pharmaceuticals Invites Investors to Listen to Webcast of Anti-Infectives Panel Discussion at RBC Capital Markets Healthcare Conference.
SAN DIEGO, Dec. 12 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. announced today that it will participate in a panel discussion entitled, "Anti-infectives: Bugs Beware" at the RBC Capital Markets Healthcare Conference on Thursday, December 14, 2006 at 11:00 a.m. EST (8:00 a.m. PST) at The Westin New York at Times...

Pharma firms rejig portfolios to cash in on lifestyle-segment boom.
Byline: Rupali Mukherjee NEW DELHI: Growing share of the lifestyle segment in the overall pharma market has led drug companies to restructure their product portfolio to tap the huge opportunity. Companies such as Alembic, in which acute therapy (anti-infectives,antibiotics) holds a dominant share, have been...

Maxiom Group and Lupin Pharmaceuticals Partner for Safety of U.S. Drug Supply.
HEALTH AND BEAUTY CLOSE-UP-28 May 2008-Maxiom Group and Lupin Pharmaceuticals Partner for Safety of U.S. Drug Supply(C)2008 - CloseUpMedia - newsdesk@closeupmedia.com Maxiom Consulting Group, a strategic business and IT consulting firm exclusively serving the life sciences industry, announced that it has partnered with Lupin Pharmaceuticals in the...

Painkillers, anti-infectives gain.
Byline: Rupali Mukherjee NEW DELHI: Growing incidence of viral infections, and diseases such as Chikungunya this year have led to a huge spurt in the sales of pain-killers and anti-infectives during the monsoon months. Sales of pain killers (anti-rheumatic, non-steroidal) shot up to over 32% during the...

DSM Anti-Infectives to launch restructuring measures.
DSM Anti-Infectives, the world's largest producer of penicillin and antibiotic products (including amoxicillins and cephalosporins), has announced a drastic package of measures, in accordance with the announcement made during the presentation of DSM's third-quarter results. The aim of the measures is to improve profitability in the short term and...

Ranbaxy enters into pact with Merck for anti-infective drugs.
NEW DELHI: Ranbaxy Laboratories has signed a strategic product development agreement with German pharma major Merck for drug discovery and clinical development collaboration in the anti-infectives field. As per the deal, the two partners will work together to develop clinically validated anti-bacterial and anti-fungal drug candidates. The agreement is...

Anti-infectives. (Drugs, Pregnancy, and Lactation).
This is my fourth and final installment on anti-infectives * Anthelmintics. All three agents in the benzimidazole class of the anthelmintics are rated pregnancy category C. In humans, their bioavailability is extremely low, but increases substantially when taken with fatty foods. There are few data...

Anti-infectives. (Drugs, Pregnancy, and Lactation).
I frequently get calls from physicians who have questions about the safety of different anti-infectives during pregnancy or breast-feeding. In this and future columns, I will review what is known about this large class of drugs when used in these two situations. * Penicillins. There is no...